GABA-B-Receptor Antibody by CBA, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Evaluating new onset encephalopathy encompassing 1 or more of the following: confusional states, psychosis, delirium, memory loss, hallucinations, seizures, dyssomnias, coma, dysautonomias, or hypoventilation
The following accompaniments should prompt suspicion for autoimmune encephalopathy:
-Autoimmune stigmata (personal or family history, or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-History of cancer
-Smoking history (20+ pack years) or other cancer risk factors
-Inflammatory cerebrospinal fluid or isolated protein elevation
-Neuroimaging signs suggesting inflammation
Evaluating limbic encephalitis
Directing a focused search for cancer
Investigating encephalopathy appearing in the course or wake of cancer therapy, and not explainable by metastasis or drug effect
Only orderable as part of an evaluation. For more information, see DEMES / Dementia, Autoimmune Evaluation, Serum; ENCES / Encephalopathy, Autoimmune Evaluation, Serum; and EPIES / Epilepsy, Autoimmune Evaluation, Serum.
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
GABA-B-R Ab CBA, S